NCT04821284View on ClinicalTrials.gov

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions
Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Nab-paclitaxel

Given IV

DRUG

Fluorouracil

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Oxaliplatin

Given IV

OTHER

Perflubutane Microbubble

Oxaliplatin

PROCEDURE

Contrast-Enhanced Ultrasound

Undergo CEUS

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (2)

5021

RECRUITING

Haukeland University Hospital, Bergen

19107

RECRUITING

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Flemming Forsberg

OTHER